This drug is not on the Reformulary. Our Expert Committee did an extensive review of the clinical and cost-effectiveness evidence, and recommended not to fund due to lack of evidence.

DOJOLVI is used to treat  
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)